bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. completed a public offering, raising approximately $3.2 million in gross proceeds. The offering included 1,040,000 shares of common stock at $0.80 per share and pre-funded warrants to purchase up to 2,960,000 shares at $0.793 per warrant. The company intends to use the net proceeds for working capital and general corporate purposes. WallachBeth Capital LLC acted as the sole placement agent, receiving a 7.5% fee and $120,000 in expense reimbursement.

bioAffinity Technologies, Inc. has filed an amendment to its S-1 registration statement, primarily updating and incorporating various exhibits. These exhibits include forms of placement agency agreements, warrants, certificates of incorporation and bylaws, as well as numerous material agreements related to employment, consulting, and past financing activities. The amendment does not appear to introduce new financial results or significant business developments beyond the incorporation of these documents.

bioAffinity Technologies announced a webinar on July 21, 2026, to discuss emerging approaches to lung health screening and early detection for veterans at increased risk for lung cancer and other respiratory diseases. The event, hosted by the National Association of Veterans’ Research and Education Foundations (NAVREF), will feature clinical experts from Philips, bioAffinity Technologies, and 4DMedical. The webinar aims to explore advances in diagnostic technologies, imaging capabilities, and strategies to improve patient access, early detection, and clinical outcomes for veterans.

bioAffinity Technologies, Inc. has filed an S-1 registration statement for an offering of 2,631,579 shares of common stock at an assumed price of $1.52 per share, with an estimated $3.4 million in proceeds intended for working capital. The company, which develops noninvasive diagnostic tests for lung cancer, also noted recent positive case studies and significant year-over-year growth in unit sales for its CyPath® Lung test in Q1 2026. It is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

bioAffinity Technologies announced that the Society for Advanced Bronchoscopy (SAB) will host a webinar on June 16, 2026, focusing on the expanding role of its noninvasive CyPath® Lung test. The webinar will feature a multidisciplinary physician panel discussing how CyPath® Lung aids in early-stage lung cancer detection, supports treatment decisions, reduces healthcare costs, and assists in post-treatment surveillance. The test has shown high sensitivity and specificity in clinical trials for high-risk patients.

bioAffinity Technologies, Inc. announced it has received notification of allowance from the Mexican Institute of Industrial Property for a patent application. This patent relates to methods of predicting the likelihood of lung cancer using flow cytometry, specifically protecting the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum. The allowance expands the company's global intellectual property portfolio for its CyPath Lung diagnostic platform, strengthening its proprietary approach to detecting early-stage lung cancer in international markets and supporting shareholder value.

bioAffinity Technologies, Inc. announced record monthly unit sales for its CyPath® Lung diagnostic test in April 2026. Sales for the noninvasive lung cancer detection test increased by nearly 300% compared to April 2025, based on preliminary unaudited data. This growth continues the trend of accelerating physician adoption and expanding clinical use, exceeding the company's internal projections. The company is focused on expanding adoption and advancing its technology platform with further clinical studies and an R&D pipeline for other respiratory diseases.

bioAffinity Technologies reported an increased net loss of $(3.63) million for the first quarter of 2026, compared to $(2.66) million in the prior year. Net revenue decreased to $1.35 million, and the company's cash and cash equivalents significantly declined to $3.1 million. Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least the next twelve months, necessitating further capital raises.

bioAffinity Technologies reported Q1 2026 financial results, with CyPath® Lung unit sales increasing 146% year-over-year and testing revenue rising 114% to $361,000. However, total consolidated revenue decreased 27% to $1.4 million due to the discontinuation of unprofitable pathology services. The company also announced a new longitudinal clinical trial for CyPath® Lung with DoD funding and a collaborative study for companion diagnostics for asthma and COPD. Net loss for the quarter was $3.6 million, or $(0.81) per share.

bioAffinity Technologies, Inc. filed an S-1 registration statement for the resale of up to 497,483 shares of common stock by selling stockholders. These shares comprise 365,603 warrant shares and 131,880 conversion shares from Series B Convertible Preferred Stock, resulting from anti-dilution adjustments. The company will not receive proceeds from the sale of these shares by selling stockholders, but could receive approximately $1.6 million if all warrants are exercised for cash. BIAF's common stock trades on The Nasdaq Capital Market under the symbol "BIAF", with a last reported sale price of $2.43 on April 29, 2026. The filing also noted recent business developments, including 146% growth in CyPath® Lung diagnostic unit sales in Q1 2026 and the enrollment of the first patient in a new lung cancer clinical trial.